| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8446551 | European Journal of Cancer | 2012 | 7 Pages |
Abstract
This retrospective data represent the largest reported series of unselected refractory mCRC patients treated with MMC. The median survival of 4.5Â months is similar to the survival expected for best supportive care. This lack of activity strongly suggests that MMC should not be routinely used in refractory mCRC.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Renata Ferrarotto, Karime Machado, Milena P. Mak, Neeraj Shah, Tiago K. Takahashi, Frederico P. Costa, Michael J. Overman, Scott Kopetz, Paulo M. Hoff,